RecruitingNCT06451796

Investigation of Novel Non-CE Marked Catheter

A Urethral Valve Catheter for the Treatment of Women With Stress Urinary Incontinence (SUI)


Sponsor

MagCath

Enrollment

20 participants

Start Date

Jun 18, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Hypothesis: Treatment with the hydrophilic coated valved intraurethral catheter up to 16 hours per day is effective, well tolerated and seemingly safe for treatment of women with stress incontinence. Test persons: Ten to twenty stress incontinent women. Treatment time: Up to two weeks


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 75 Years

Inclusion Criteria9

  • Willing to participate
  • Adult, competent woman who understands Danish.
  • SUI as dominant symptom; daily or almost daily.
  • Residual urine < 150 ml.
  • POP-Q prolapse ≤ grade 2.
  • Negative urine stix/Urine D+R.
  • Min. 2 months local vaginal estrogen treatment if the woman is postmenopausal.
  • Mobile and self-reliant woman.
  • Motivated.

Exclusion Criteria9

  • Allergy to the silicone material
  • Pregnancy or breastfeeding
  • Unexplained hematuria.
  • Current inflammatory disorders
  • Malignant disorders of the urethra.
  • Urethral stricture
  • Visual diverticulum.
  • AK treatment.
  • Prosthetic heart valve surgery.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEObtinu

Treatment of Female Stress Incontinence with a hydrophilic coated valved intraurethral catheter


Locations(1)

GynCare

Herlev, DK, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06451796